IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”). The award was approved by the Company’s Compensation Committee, which is comprised of independent directors, on […]
Financial
Hemostemix Announces Corporate Update
CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF) is pleased to announce the appointment of David Wood to the position of Chairman, Bryson Goodwin to the position of Chief Executive Officer, Thomas Smeenk to the position of President, and […]
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the pricing of the previously-announced underwritten secondary offering by […]
Endonovo Therapeutics Announces Reverse Stock Split – UPDATE
Los Angeles, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect, and the Company’s common stock will begin […]
Resverlogix Announces Change to its Board of Directors
CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today. “We would like to thank Eldon for his many years of service and wish him all the best,” […]
FEops Awarded Euro 3.2 Million Grant From EU
GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, has been awarded a grant of Euro 3.2 million from the European Innovation Council (EIC) accelerator programme. “We are very proud to receive this grant, given the fierce competition. This ranks us now in the top 4% of all […]
InspireMD Announces Planned Leadership Transition
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused […]
Orchestra BioMed™ Secures $20 Million Financing Facility from Silicon Valley Bank
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank (SVB), the bank of the world’s most […]
Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation
NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ and the Toronto Stock Exchange (TSX) have halted trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal […]
Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America
Biolab Sanus Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of arterial hypertension in Latin America PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the […]



